UmanDiagnostics AB

https://www.umandiagnostics.com

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has entered into a definitive agreement to acquire privately held UmanDiagnostics AB for $22.5 million, comprised of $16 million in cash plus $6.5 million in Quanterix common stock. Uman is widely recognized to possess the leading antibodies available today to measure neurofilament light (Nf-L) and has become the provider of choice for biopharmaceutical and diagnostic applications. Uman, based in Umeå, Sweden, supplies Nf-L antibodies and ELISA kits, which are widely recognized by researchers and biopharmaceutical and diagnostics companies world-wide as the premier solution for the detection of Nf-L to advance the development of therapeutics and diagnostics for neurodegenerative conditions. Nf-L has seen a dramatic growth in the last three years since Quanterix developed the first assay using Uman’s antibodies that could reliably measure Nf-L in blood. This innovation allowed research, previously limited primarily to cerebrospinal fluid (CSF), to expand significantly and has led many of the world’s foremost neurology researchers and clinicians to conclude that Nf-L may be the most clinically relevant brain biomarker available today. Nf-L has demonstrated utility in the diagnosis, prognosis, and monitoring of a wide range of conditions including Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, traumatic brain injury (TBI), ALS, Huntington’s Disease, and others. *

	Start	2006-01-01 established
	Group	Quanterix (Group)
	Industry	Nf-L antibody (neurofilament light antibody)
	Industry 2	ELISA assay (diagnostics) (enzyme linked immunosorbent assay)
	Person	Norgren, Niklas (UmanDiagnostics 201906 CEO)

	Region	Umeå
	Country	Sweden
	Street	48 C Tvistevägen
	City	90736 Umeå
	Tel	+46-90-777-880
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Quanterix Corporation. (6/26/19). "Press Release: Quanterix Announces Agreement to Acquire UmanDiagnostics, World’s Leading Neurofilament Light (Nf-L) Antibody Supplier". Billerica, MA.

		Record changed: 2025-03-16